Benefits of Icosapent Ethyl Across the Range of Kidney Function in Patients With Established Cardiovascular Disease or Diabetes: REDUCE-IT RENAL
Authors: Majithia Arjun , Bhatt Deepak L. , Friedman Allon N. , Miller Michael , Steg Ph. Gabriel , Brinton Eliot A. , Jacobson Terry A. , Ketchum Steven B. , Juliano Rebecca A. , Jiao Lixia , Doyle Ralph T. , Granowitz Craig , Budoff Matthew , Preston Mason R. , Tardif Jean-Claude , Boden William E. , Ballantyne Christie M. ,   on behalf of the REDUCE-IT Investigators
Published: October 2021

Background:
Chronic kidney disease is associated with adverse outcomes among patients with established cardiovascular disease (CVD) or diabetes. Commonly used medications to treat CVD are less effective among patients with reduced kidney function.

Methods:
REDUCE-IT (Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial) was a multicenter, double-blind, placebo-controlled trial that randomly assigned statin-treated patients with elevated triglycerides (135–499 mg/dL) who had CVD or diabetes and 1 additional risk factor to treatment with icosapent ethyl (4 g daily) or placebo. Patients from REDUCE-IT were categorized by prespecified estimated glomerular filtration rate (eGFR) categories to analyze the effect of icosapent ethyl on the primary end point (composite of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, coronary revascularization, or unstable angina) and key secondary end point (a composite of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke).

Results:

Among the 8179 REDUCE-IT patients, median baseline eGFR was 75 mL·min
–1
·1.73 m
–2
(range, 17–123 mL·min
–1
·1.73 m
–2
). There were no meaningful changes in median eGFR for icosapent ethyl versus placebo across study visits. Treatment with icosapent ethyl led to consistent reduction in both the primary and key secondary composite end points across baseline eGFR categories. Patients with eGFR <60 mL·min
–1
·1.73 m
–2
treated with icosapent ethyl had the largest absolute and similar relative risk reduction for the primary composite end point (icosapent ethyl versus placebo, 21.8% versus 28.9%; hazard ratio [HR], 0.71 [95% CI, 0.59–0.85];
P
=0.0002) and key secondary composite end point (16.8% versus 22.5%; HR 0.71 [95% CI, 0.57–0.88];
P
=0.001). The numeric reduction in cardiovascular death was greatest in the eGFR <60 mL·min
–1
·1.73 m
–2
group (icosapent ethyl: 7.6%; placebo: 10.6%; HR, 0.70 [95% CI, 0.51–0.95];
P
=0.02). Although patients with eGFR <60 mL·min
–1
·1.73 m
–2
treated with icosapent ethyl had the highest numeric rates of atrial fibrillation/flutter (icosapent ethyl: 4.2%; placebo 3.0%; HR 1.42 [95% CI, 0.86–2.32];
P
=0.17) and serious bleeding (icosapent ethyl: 5.4%; placebo 3.6%; HR, 1.40 [95% CI, 0.90–2.18];
P
=0.13), HRs for atrial fibrillation/flutter and serious bleeding were similar across eGFR categories (
P
-interaction for atrial fibrillation/flutter=0.92;
P
-interaction for serious bleeding=0.76).

Conclusions:
In REDUCE-IT, icosapent ethyl reduced fatal and nonfatal ischemic events across the broad range of baseline eGFR categories.

REGISTRATION:
URL:
https://www.clinicaltrials.gov
; Unique identifier: NCT01492361